Litron Laboratories, Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4
Ending by 2030
May 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 15, 2027The maintenance fee for Rapid in vivo gene mutation assay based on the Pig-A gene (US 9,133,505) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
- 1 fee due May 28, 2027The maintenance fee for Simplified nuclei analysis platform and biomarker matrix that supports genotoxic mode of action determinations (US 11,828,763) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 10 of 10
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,062,860 | Kit for measuring in vivo mutation frequency at an endogenous gene locus In force · From the USPTO record | In force | From the USPTO record | |
| US 7,824,874 | Method for measuring in vivo mutation frequency at an endogenous gene locus In force · From the USPTO record | In force | From the USPTO record | |
| US 8,062,222 | Method for measuring in vivo hematotoxicity with an emphasis on radiation exposure assessment In force · From the USPTO record | In force | From the USPTO record | |
| US 8,187,826 | Quantitative analysis of in vivo mutation at the Pig-A locus In force · From the USPTO record | In force | From the USPTO record | |
| US 9,133,505 | Rapid in vivo gene mutation assay based on the Pig-A gene In force · From the USPTO record | In force | From the USPTO record | |
| US 9,470,694 | Simplified nuclei analysis platform and biomarker matrix that supports genotoxic mode of action determinations In force · From the USPTO record | In force | From the USPTO record | |
| US 9,857,358 | Simplified nuclei analysis platform and biomarker matrix that supports genotoxic mode of action determinations In force · From the USPTO record | In force | From the USPTO record | |
| US 10,802,013 | Simplified nuclei analysis platform and biomarker matrix that supports genotoxic mode of action determinations In force · From the USPTO record | In force | From the USPTO record | |
| US 11,016,101 | Simplified nuclei analysis platform and biomarker matrix that supports genotoxic mode of action determinations In force · From the USPTO record | In force | From the USPTO record | |
| US 11,828,763 | Simplified nuclei analysis platform and biomarker matrix that supports genotoxic mode of action determinations In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 10: 1 lapsed for an unpaid fee · 14 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 no status recorded